Hemovigilance programs have been launched by several countries to address the noninfectious hazards of transfusion. Of particular interest is the prevention of hemolytic transfusion reactions. Matching blood transfusion to the transfusion recipient antigen profile has been a long-standing therapy to address and further prevent red cell alloimmunization. Last year we learned of the comorbidities associated with delayed hemolytic transfusion reactions and that as many as 80% of alloimmune responses become undetectable by the next transfusion. What can be done to address red cell alloimmunization? This education session is designed to challenge physicians and laboratorians to think about broad-based ways to mitigate immune hazards of transfusion: alloantibody registries, antigen-negative blood and genotype dry matching of red cells including the use of historical antigen typings all play a role. Come to this session for a review of the clinical impact of hemolytic transfusion reactions and importance of alloantibody detection in the chronic transfusion recipient, the advantages of historical red cells phenotypes/genotypes on the delivery of safe blood products for transfusion and the impact of a hemovigilance program.

Gary Stack did not consent to be recorded.